CTOs on the Move

Terumo Interventional Systems

www.terumois.com

 
Terumo Interventional Systems is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.terumois.com
  • 2101 Cottontail Ln
    Somerset, NJ USA 08873
  • Phone: 732.302.4900

Executives

Name Title Contact Details

Similar Companies

Skyhawk Therapeutics

Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression.

Total Repair Express

Total Repair Express is a Hillsborough, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Research and Diagnostic Systems

Research and Diagnostic Systems is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlobeImmune

GlobeImmune is a Louisville, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body`s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno`s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world`s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children`s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children`s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children`s Research Hospital.